Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
BrainCool AB (publ), a medical technology company founded in 2010 and headquartered in Lund, Sweden, focuses on the development, commercialization, and distribution of advanced medical cooling systems. Operating with its subsidiaries, the company caters to the healthcare sector, primarily serving the Swedish market, by providing innovative solutions for various conditions including stroke, sudden cardiac arrest, oral mucositis, and migraine. Their product line features the BrainCool and RhinoChill systems, specifically engineered to deliver swift therapeutic cooling in emergency situations, thereby ensuring uninterrupted patient care. To mitigate the risk of oral mucositis, BrainCool offers the Cooral system, renowned for its user-friendly design for medical professionals. Furthermore, the IQool system boasts an intuitive interface complemented by informative graphics and an automatic feedback loop, empowering clinicians to dedicate their attention to patient management rather than device operation.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of BRAIN.ST is 1.00 and suggests 0% downside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommenda